The Experts below are selected from a list of 27111 Experts worldwide ranked by ideXlab platform

Jonathan J. Gregory - One of the best experts on this subject based on the ideXlab platform.

  • THE USE OF NEO-Adjuvant Radiotherapy IN THE MANAGEMENT OF PERIARTICULAR SOFT TISSUE SARCOMA
    2018
    Co-Authors: C Green, Nam Nguyen, J Wylie, A Choudhury, Jonathan J. Gregory
    Abstract:

    Optimising post-operative joint function is challenging when treating periarticular soft tissue sarcoma (STS). Radiotherapy reduces local recurrence rates but periarticular fibrosis may adversely affect joint function. Neo-Adjuvant Radiotherapy requires lower doses and smaller treatment volumes and therefore has potential benefits for the management of periarticular STS, but may lead to an increased risk of post-operative wound complications. This study assesses initial outcome and complications after treatment with neo-Adjuvant Radiotherapy and surgery for patients with periarticular STS.17 patients treated with neo-Adjuvant Radiotherapy and surgery were identified. 3D conformal Radiotherapy was delivered at a single centre with a dose of 50Gy in 25 fractions over 5 weeks. Patients were assessed weekly for adverse effects. Resection was planned 4–6 weeks after Radiotherapy.Median follow-up was 13 months (range 5–44 months). No patients had significant adverse effects during Radiotherapy. One patient had ...

  • The treatment of periarticular soft tissue sarcoma following neo-Adjuvant Radiotherapy: a cohort study
    World journal of surgical oncology, 2015
    Co-Authors: C Green, Nam Nguyen, A Choudhury, James D. Wylie, Jonathan J. Gregory
    Abstract:

    Background Optimising post-operative joint function is challenging when treating periarticular soft tissue sarcoma (STS). Radiotherapy reduces local recurrence rates but periarticular fibrosis may adversely affect joint function. Neo-Adjuvant Radiotherapy requires lower doses and smaller treatment volumes and therefore has potential benefits for the management of periarticular STS, but has previously been shown to be associated with an increased risk of post-operative wound complications. This study assesses initial outcome and complications after treatment with neo-Adjuvant Radiotherapy and surgery for patients with periarticular STS.

  • THE USE OF NEO-Adjuvant Radiotherapy IN THE MANAGEMENT OF PERIARTICULAR SOFT TISSUE SARCOMA
    Journal of Bone and Joint Surgery-british Volume, 2013
    Co-Authors: C Green, Nam Nguyen, J Wylie, A Choudhury, Jonathan J. Gregory
    Abstract:

    Optimising post-operative joint function is challenging when treating periarticular soft tissue sarcoma (STS). Radiotherapy reduces local recurrence rates but periarticular fibrosis may adversely affect joint function. Neo-Adjuvant Radiotherapy requires lower doses and smaller treatment volumes and therefore has potential benefits for the management of periarticular STS, but may lead to an increased risk of post-operative wound complications. This study assesses initial outcome and complications after treatment with neo-Adjuvant Radiotherapy and surgery for patients with periarticular STS. 17 patients treated with neo-Adjuvant Radiotherapy and surgery were identified. 3D conformal Radiotherapy was delivered at a single centre with a dose of 50Gy in 25 fractions over 5 weeks. Patients were assessed weekly for adverse effects. Resection was planned 4–6 weeks after Radiotherapy. Median follow-up was 13 months (range 5–44 months). No patients had significant adverse effects during Radiotherapy. One patient had surgery delayed due to local skin reaction. Minor complications in five patients (three superficial infections, one seroma, one neuropraxia). One patient required further surgery due to incomplete margins. TESS scores for upper and lower limb patients were 86.1 and 78.1 respectively. No cases of local recurrence have occurred to date. Two patients have developed distant metastatic disease. The early results for periarticular STS managed with neo-Adjuvant Radiotherapy and surgery are excellent. There does not appear to be a significant increase in post-operative complication rates. With neo-Adjuvant Radiotherapy. Long term follow-up is required to demonstrate final functional outcome and local control rates.

Mark L Gonzalgo - One of the best experts on this subject based on the ideXlab platform.

  • stage i testicular seminoma a seer analysis of contemporary Adjuvant Radiotherapy trends
    The Journal of Urology, 2013
    Co-Authors: Alan Thong, Daphne Y Lichtensztajn, Leanne Almario, Alexandre Ingels, Scarlett Lin Gomez, Mark L Gonzalgo
    Abstract:

    Purpose: Patients with clinical stage I testicular seminoma have historically been treated with Adjuvant Radiotherapy in the United States. However, nearly 80% of patients on surveillance will not experience relapse and even with relapse, salvage rates approach 100%. It remains unclear how practice patterns have changed with recently accumulating evidence and changes in guidelines. In a population based setting we evaluated contemporary trends and factors that may affect the use of Adjuvant Radiotherapy.Materials and Methods: A total of 8,151 men diagnosed with stage I testicular seminoma from 2000 to 2009 were identified in the national SEER (Surveillance, Epidemiology, and End Results) registry. A multivariate regression model was constructed to analyze the association of year, age, race, socioeconomic status, SEER region, pathological stage and tumor size with the administration of Adjuvant Radiotherapy.Results: The use of Adjuvant Radiotherapy decreased significantly from 2000 to 2009. In 2000, 74.7% ...

Scarlett Lin Gomez - One of the best experts on this subject based on the ideXlab platform.

  • stage i testicular seminoma a seer analysis of contemporary Adjuvant Radiotherapy trends
    The Journal of Urology, 2013
    Co-Authors: Alan Thong, Daphne Y Lichtensztajn, Leanne Almario, Alexandre Ingels, Scarlett Lin Gomez, Mark L Gonzalgo
    Abstract:

    Purpose: Patients with clinical stage I testicular seminoma have historically been treated with Adjuvant Radiotherapy in the United States. However, nearly 80% of patients on surveillance will not experience relapse and even with relapse, salvage rates approach 100%. It remains unclear how practice patterns have changed with recently accumulating evidence and changes in guidelines. In a population based setting we evaluated contemporary trends and factors that may affect the use of Adjuvant Radiotherapy.Materials and Methods: A total of 8,151 men diagnosed with stage I testicular seminoma from 2000 to 2009 were identified in the national SEER (Surveillance, Epidemiology, and End Results) registry. A multivariate regression model was constructed to analyze the association of year, age, race, socioeconomic status, SEER region, pathological stage and tumor size with the administration of Adjuvant Radiotherapy.Results: The use of Adjuvant Radiotherapy decreased significantly from 2000 to 2009. In 2000, 74.7% ...

Frédéric Amant - One of the best experts on this subject based on the ideXlab platform.

  • Characteristics and prognosis of patients with early-stage endometrial cancer who refuse Adjuvant Radiotherapy.
    Gynecologic oncology, 2016
    Co-Authors: Martin Koskas, Cyrille Huchon, Frédéric Amant
    Abstract:

    Abstract Objective To investigate the risk factors for refusing Adjuvant Radiotherapy in patients who have undergone surgery for early-stage endometrial cancer, and to compare their survival rates with patients who have undergone Adjuvant Radiotherapy. Methods Data from the Surveillance, Epidemiology, and End Results database for patients operated on for histologically-proven early-stage endometrioid endometrial cancer, between 1988 and 2012, were screened. Univariate and multivariate logistic regression analyses tested the associations between refusal of Adjuvant Radiotherapy and demographic, tumoral, and management characteristics. Overall and cancer-related survival rates were compared between 376 patients who refused Adjuvant Radiotherapy and 752 patients who received Adjuvant Radiotherapy, matched for demographics (age, race, year of diagnosis, marital status, region), tumoral (grade, FIGO stage, size), and management (lymphadenectomy performed) criteria. Results 434 of the 16,014 patients (2.7%) who were proposed Adjuvant Radiotherapy refused this treatment. Older, widowed, divorced, or separated patients, who were recently diagnosed and managed in the Northern plains or Pacific coast (USA), with limited tumoral extension, were more likely to refuse Adjuvant Radiotherapy. Five-year cancer-related survival was significantly lower in patients who refused Adjuvant Radiotherapy (88.9% vs. 95.7%, p p =0.23). Conclusions We have identified the patients' characteristics related to refusal of Adjuvant Radiotherapy. Refusing Adjuvant Radiotherapy increased cancer-related death but probably does not reduce overall survival.

  • Characteristics and prognosis of patients with early-stage endometrial cancer who refuse Adjuvant Radiotherapy
    Gynecologic Oncology, 2016
    Co-Authors: Martin Koskas, Cyrille Huchon, Frédéric Amant
    Abstract:

    Objective To investigate the risk factors for refusing Adjuvant Radiotherapy in patients who have undergone surgery for early-stage endometrial cancer, and to compare their survival rates with patients who have undergone Adjuvant Radiotherapy. Methods Data from the Surveillance, Epidemiology, and End Results database for patients operated on for histologically-proven early-stage endometrioid endometrial cancer, between 1988 and 2012, were screened. Univariate and multivariate logistic regression analyses tested the associations between refusal of Adjuvant Radiotherapy and demographic, tumoral, and management characteristics. Overall and cancer-related survival rates were compared between 376 patients who refused Adjuvant Radiotherapy and 752 patients who received Adjuvant Radiotherapy, matched for demographics (age, race, year of diagnosis, marital status, region), tumoral (grade, FIGO stage, size), and management (lymphadenectomy performed) criteria. Results 434 of the 16,014 patients (2.7%) who were proposed Adjuvant Radiotherapy refused this treatment. Older, widowed, divorced, or separated patients, who were recently diagnosed and managed in the Northern plains or Pacific coast (USA), with limited tumoral extension, were more likely to refuse Adjuvant Radiotherapy. Five-year cancer-related survival was significantly lower in patients who refused Adjuvant Radiotherapy (88.9% vs. 95.7%, p < 0.001) whereas overall survival did not significantly differ between the two groups (76.4% vs. 83.7%, p = 0.23). Conclusions We have identified the patients’ characteristics related to refusal of Adjuvant Radiotherapy. Refusing Adjuvant Radiotherapy increased cancer-related death but probably does not reduce overall survival.

Atanas Ignatov - One of the best experts on this subject based on the ideXlab platform.